Heteroaryl substituted beta-hydroxyethylamines for use in treating hyperglycaemia
There is herein provided a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein the ring containing Q 1 to Q 5 , and the groups R 1 , R 2 and R 3 , have meanings as provided in the description.
1. A compound of the following formula:
or a pharmaceutically acceptable salt thereof.
2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein the compound is present in an enantiomeric excess (e.e.) of at least 90%.
3. A pharmaceutical composition comprising a compound as defined in claim 1 , or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable adjuvant, diluent and/or carrier.
4. The pharmaceutical composition of claim 3 , wherein the compound is present in an enantiomeric excess (e.e.) of at least 90%.
5. A combination product comprising:
(a) a compound as defined in claim 1 , or a pharmaceutically acceptable salt thereof; and
(b) one or more other therapeutic agent that is useful in the treatment of hyperglycaemia or a disorder characterized by hyperglycaemia,
wherein each of components (a) and (b) is formulated in admixture, optionally with one or more a pharmaceutically-acceptable adjuvant, diluent and/or carrier.
6. The combination product of claim 5 , wherein the compound is present in an enantiomeric excess (e.e.) of at least 90%.
7. A kit-of-parts comprising:
(a) a pharmaceutical composition comprising a compound as defined in claim 1 , or a pharmaceutically acceptable salt thereof, and optionally one or more pharmaceutically acceptable adjuvant, diluent and/or carrier, and
(b) one or more other therapeutic agent that is useful in the treatment of hyperglycaemia or a disorder characterized by hyperglycaemia, optionally in admixture with one or more pharmaceutically-acceptable adjuvant, diluent and/or carrier,
which components (a) and (b) are each provided in a form that is suitable for administration in conjunction with the other.
8. The kit of claim 7 , wherein the compound is present in an enantiomeric excess (e.e.) of at least 90%.